Artikel
Fluorescence-optical imaging technique discriminates signs of early joint inflammation in patients suspect of Rheumatoid Arthritis in the PANORA trial
Suche in Medline nach
Autoren
Veröffentlicht: | 14. September 2021 |
---|
Gliederung
Text
Introduction: Rheumatoid Arthritis (RA) is a chronic inflammatory joint disease affecting about 1% of the European adults. Fluorescence-optical imaging (FOI) technique is an indocyanine-green (ICG) based procedure to assess changes of microvascularization in the hands. Purpose of the study was to investigate if assessment of FOI is of value for early detection and prediction of RA in the ‘at-risk’ population.
Methods: In the PANORA trial, 980 patients with new onset of nsMSK symptoms were recruited by a network of General Practicioners (GP). In case of positivity in anti-CCP point-of-care test (CCPoint®), patients were referred to Rheumatology Department (RD) for further assessments: confirmation of anti-CCP positivity via ELISA, physical examination, joint assessment, ultrasound. Additionally, FOI was performed and assessed using FOIAS (fluorescence optical imaging activity score) according to ICG-distribution [1], [2], [3]. Patients were followed up for 3 years or until RA was diagnosed.
Results: Of the 980 patients, 9.8% (n=94) showed a positive CCPoint® test and were referred to RD. At RD, 21% (n=25) were confirmed anti-CCP-positive by ELISA from which 11 patients were diagnosed with RA at their first visit, 6 in the follow-up (FU) period. FOI assessment showed increased signal intensities (mean) in FOIAS phase (P) 2 in the patients with RA (18.0 vs. 11.6) as well as in the mean P1+P2+P3 (19.8 vs. 16.8 for the no-RA group). Compared to the RA and no RA group from first visit, mean P1+P2+P3 showed increased levels at first visit in the ELISA positive group which developed RA later during follow-up (23.8).
Conclusion: Data from patients suspect of RA and screened using CCPoint® test at GP before referral to RD are reported. FOI assessment discriminates patients with RA to those without by assessment of P2 and P1+P2+P3. Moreover, levels for P1+P2+P3 are increased in the ELISA positive cohort which developed RA later in the FU period. So, FOI might be useful not only in early diagnosis of RA in the ‘at risk’ population, but also for prediction of RA and of additional use for early diagnostic beside serological biomarkers.
Disclosures: Das Forschungsprojekt wurde durch eine Forschungsförderung der Firma BMS gefördert.
References
- 1.
- Werner SG, Langer HE, Ohrndorf S, Bahner M, Schott P, Schwenke C, Schirner M, Bastian H, Lind-Albrecht G, Kurtz B, Burmester GR, Backhaus M. Inflammation assessment in patients with arthritis using a novel in vivo fluorescence optical imaging technology. Ann Rheum Dis. 2012 Apr;71(4):504-10. DOI: 10.1136/annrheumdis-2010-148288
- 2.
- Werner SG, Langer HE, Schott P, Bahner M, Schwenke C, Lind-Albrecht G, Spiecker F, Kurtz B, Burmester GR, Backhaus M. Indocyanine green-enhanced fluorescence optical imaging in patients with early and very early arthritis: a comparative study with magnetic resonance imaging. Arthritis Rheum. 2013 Dec;65(12):3036-44. DOI: 10.1002/art.38175
- 3.
- Glimm AM, Werner SG, Burmester GR, Backhaus M, Ohrndorf S. Analysis of distribution and severity of inflammationin patients with osteoarthitis compared to rheumatoid arthritis by ICG-enhanced fluorescence optical imaging and musculoskeletal ultrasound: a pilot study. Ann Rheum Dis. 2016 Mar;75(3):566-70. DOI: 10.1136/annrheumdis-2015-20734